Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202

Journal of Acquired Immune Deficiency Syndromes

Volumn 65, Issue 2, 2014, Pages 167-174

  McComsey, Grace A ^a   Kitch, Douglas ^b   Sax, Paul E ^c   Tierney, Camlin ^b   Jahed, Nasreen C ^d   Melbourne, Kathleen ^e   Ha, Belinda ^f   Brown, Todd T ^g   Bloom, Anthony ^h   Fedarko, Neal ^g   Daar, Eric S ⁱ  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^e GILEAD SCIENCES   (United States)

^f GLAXOSMITHKLINE   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

ⁱ LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

AIDS events; C reactive protein; Endothelial activation markers; Inflammation markers; Interleukin 6; Non AIDS events; TNF

Indexed keywords

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84893799273     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/01.qai.0000437171.00504.41     Document Type: Article

References (19)

1. Neaton JD, Neuhaus J, Emery S. Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010. Curr Opin HIV AIDS. 2010;5:480-490. PMCID: 3079321.
2. Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, Ddimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis. 2011;203:1637-1646. PMCID: 3096784.
3. Medrano FJ, Leal M, Arienti D, et al. Tumor necrosis factor beta and soluble APO-1/Fas independently predict progression to AIDS in HIVseropositive patients. AIDS Res Hum Retroviruses. 1998;14:835-843.
4. Zangerle R, Steinhuber S, Sarcletti M, et al. Serum HIV-1 RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1-infected individuals. Int Arch Allergy Immunol. 1998;116:228-239.
5. Havlir DV, Torriani FJ, Schrier RD, et al. Serum interleukin-6 (IL-6), IL- 10, tumor necrosis factor (TNF) alpha, soluble type II TNF receptor, and transforming growth factor beta levels in human immunodeficiency virus type 1-infected individuals with Mycobacterium avium complex disease. J Clin Microbiol. 2001;39:298-303. PMCID: 87718.
6. McComsey GA, Kitch D, Daar ES, et al. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir: ACTG A5224 s, A5202 substudy. AIDS. 2012;26:1371-1385.
7. Overton ET, Kitch D, Benson CA, et al. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis. 2013;56:1471-1479.
8. McComsey G, Kitch D, Daar E, et al. Bone mineral density and fractures in antiretroviral-naive subjects randomized to abacavir/lamivudine or tenofovir disoproxil fumarate/emtricitabine along with efavirenz or atazanavir/ ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203:1791-1801.
9. McComsey G, Kitch D, Sax PE, et al. Peripheral and central fat changes in subjects randomized to abacavir/lamivudine or tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz: ACTG study A5224s. Clin Infect Dis. 2011;53:185-196.
10. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203. PMCID: 2570418.
11. Feldman JG, Goldwasser P, Holman S, et al. C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr. 2003;32:210-214.
12. Drain PK, Kupka R, Msamanga GI, et al. C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting. AIDS. 2007;21:2067-2075.
13. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr. 2009;51:268-273. PMCID: 2763381.
14. Ross AC, Rizk N, O'Riordan MA, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis. 2009;49:1119-1127.
15. Ross AC, O'Riordan MA, Storer N, et al. Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children. Atherosclerosis. 2010;211:492-498.
16. Kalayjian RC, Machekano RN, Rizk N, et al. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis. 2010;201:1796-1805. PMCID: 2873127.
17. Brown TT, Tassiopoulos K, Bosch RJ, et al. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care. 2010;33:2244-2249. PMCID: 2945167.
18. Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009;51:554-561.
19. Peduzzi P, Concato J, Feinstein AR, et al. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48:1503-1510.